2025-05-27
PCOS: Is homocysteine the hidden fertility marker?
Endocrinology and Metabolism
#PCOS #Fertility
#Homocysteine #Oocyte #Micronutrients #IVF #Methylation
Polycystic ovary syndrome (PCOS) is a complex endocrine disorder that affects approximately 20% of women of reproductive age. It is characterized by chronic hormonal imbalance, persistent anovulation, and polycystic ovarian morphology on ultrasound. Beyond its clinical manifestations, PCOS is currently one of the leading causes of female infertility worldwide.
Assessing fertility in this context remains a true clinical challenge. Despite medical advances, the identification of reliable biomarkers for oocyte quality is still lacking. Current approaches are often imprecise, poorly reproducible, and do not always reflect the potential for embryo development. This uncertainty is even greater in women with PCOS, whose follicular environment is profoundly altered metabolically, inflammatory-wise, and oxidatively.
Against this backdrop, homocysteine (Hcy) is generating growing interest. Involved in key metabolic pathways such as DNA methylation, Hcy becomes toxic when deregulated. Excess Hcy inhibits methylation processes, increases oxidative stress, and disrupts cellular homeostasis. These alterations may directly impair the quality of the follicular microenvironment, which is essential for oocyte maturation and competence. In women with PCOS, elevated homocysteine levels have been associated with poorer oocyte quality and less favorable IVF outcomes. However, data remain scarce and incomplete, and very few studies have specifically examined homocysteine concentrations in follicular fluid and their direct relationship to oocyte fertility in PCOS.
This study was therefore launched to better characterize follicular Hcy as a potential predictive marker of oocyte quality in women with PCOS. Such data may pave the way for new personalized care strategies, particularly within assisted reproductive technologies (ART).
In this study, 48 women with PCOS undergoing IVF protocols were selected and divided into two groups:
Treatment was administered for two months before ovarian stimulation and continued until oocyte retrieval. After embryo transfer, the follicles from which transferred embryos originated were analyzed to determine their homocysteine concentration.
The results show a negative correlation between follicular Hcy levels and pregnancy occurrence. No pregnancies were observed when follicular Hcy exceeded 10.5 μmol/L, with one exception. Although not statistically significant, median Hcy concentrations were lower in women who received micronutrients. Clinically, the observed effects are promising: supplemented patients required less FSH to reach ovulation trigger, indicating better ovarian response. Their blastocyst rate was higher, suggesting improved embryo quality, and there was also a trend toward higher implantation and clinical pregnancy rates. These findings suggest that follicular Hcy could become a useful marker of oocyte quality in PCOS, and that its modulation through nutrition might improve IVF success rates.
PCOS is a common endocrine condition associated with disruptions in the follicular microenvironment and reduced fertility. One of the major challenges lies in the difficulty of predicting oocyte quality due to the lack of reliable local biomarkers, and because blood Hcy levels poorly reflect the metabolic state within the follicle.
This study aimed to evaluate whether Hcy concentration in follicular fluid could serve as a predictive marker of oocyte competence, and whether it could be modulated through micronutrient supplementation targeting Hcy metabolism.
The results suggest that follicular Hcy could become a useful and non-invasive indicator of oocyte quality, more relevant than plasma Hcy. Its measurement could enrich embryo selection strategies in IVF. Furthermore, micronutrient supplementation appears to improve ovarian response, embryo quality, and implantation rates, even without a significant reduction in Hcy levels.
These initial findings pave the way for new nutritional approaches in the management of PCOS-related infertility. Larger studies—including women without PCOS—will be needed to confirm the value of follicular Hcy as a reproductive biomarker and to validate the effect of micronutrient interventions on fertility.
Polycystic ovary syndrome (PCOS) is a complex endocrine disorder that affects approximately 20% of women of reproductive age. It is characterized by chronic hormonal imbalance, persistent anovulation, and polycystic ovarian morphology on ultrasound. Beyond its clinical manifestations, PCOS is currently one of the leading causes of female infertility worldwide.
Assessing fertility in this context remains a true clinical challenge. Despite medical advances, the identification of reliable biomarkers for oocyte quality is still lacking. Current approaches are often imprecise, poorly reproducible, and do not always reflect the potential for embryo development. This uncertainty is even greater in women with PCOS, whose follicular environment is profoundly altered metabolically, inflammatory-wise, and oxidatively.
Against this backdrop, homocysteine (Hcy) is generating growing interest. Involved in key metabolic pathways such as DNA methylation, Hcy becomes toxic when deregulated. Excess Hcy inhibits methylation processes, increases oxidative stress, and disrupts cellular homeostasis. These alterations may directly impair the quality of the follicular microenvironment, which is essential for oocyte maturation and competence. In women with PCOS, elevated homocysteine levels have been associated with poorer oocyte quality and less favorable IVF outcomes. However, data remain scarce and incomplete, and very few studies have specifically examined homocysteine concentrations in follicular fluid and their direct relationship to oocyte fertility in PCOS.
This study was therefore launched to better characterize follicular Hcy as a potential predictive marker of oocyte quality in women with PCOS. Such data may pave the way for new personalized care strategies, particularly within assisted reproductive technologies (ART).
Is it all about the follicle?
In this study, 48 women with PCOS undergoing IVF protocols were selected and divided into two groups:
- Control group: no supplementation.
- Intervention group: daily micronutrient supplementation (folates, vitamins B2, B3, B6, B12, zinc, cystine, and betaine) targeting homocysteine metabolism.
Treatment was administered for two months before ovarian stimulation and continued until oocyte retrieval. After embryo transfer, the follicles from which transferred embryos originated were analyzed to determine their homocysteine concentration.
The results show a negative correlation between follicular Hcy levels and pregnancy occurrence. No pregnancies were observed when follicular Hcy exceeded 10.5 μmol/L, with one exception. Although not statistically significant, median Hcy concentrations were lower in women who received micronutrients. Clinically, the observed effects are promising: supplemented patients required less FSH to reach ovulation trigger, indicating better ovarian response. Their blastocyst rate was higher, suggesting improved embryo quality, and there was also a trend toward higher implantation and clinical pregnancy rates. These findings suggest that follicular Hcy could become a useful marker of oocyte quality in PCOS, and that its modulation through nutrition might improve IVF success rates.
Read next: Hormones: should we really fear fat?
Homocysteine: key indicator, targeted hope
PCOS is a common endocrine condition associated with disruptions in the follicular microenvironment and reduced fertility. One of the major challenges lies in the difficulty of predicting oocyte quality due to the lack of reliable local biomarkers, and because blood Hcy levels poorly reflect the metabolic state within the follicle.
This study aimed to evaluate whether Hcy concentration in follicular fluid could serve as a predictive marker of oocyte competence, and whether it could be modulated through micronutrient supplementation targeting Hcy metabolism.
The results suggest that follicular Hcy could become a useful and non-invasive indicator of oocyte quality, more relevant than plasma Hcy. Its measurement could enrich embryo selection strategies in IVF. Furthermore, micronutrient supplementation appears to improve ovarian response, embryo quality, and implantation rates, even without a significant reduction in Hcy levels.
These initial findings pave the way for new nutritional approaches in the management of PCOS-related infertility. Larger studies—including women without PCOS—will be needed to confirm the value of follicular Hcy as a reproductive biomarker and to validate the effect of micronutrient interventions on fertility.
Read next: Astaxanthin: a promising supplement to reduce inflammation and cellular stress in PCOS
Last press reviews
Breathing can kill—even without smoking.
#Nicotine #SecondhandSmoke #LungCancer #Prevention &nb...
